DNA Repair Genes and Antiblastoma Defense
The maintenance of genetic stability relies on DNA repair genes, which act as the primary defense mechanism against tumorigenesis at the genomic level. During normal cellular proliferation or under the aggressive influence of environmental carcinogens, DNA structures inevitably sustain damage. The primary function of repair genes is to recognize these defects in a timely manner and restore the normal nucleotide sequence.
The pathogenesis of tumor growth is closely linked to the disruption of this protective system. Loss of function, somatic mutation, or inherited congenital defects in DNA repair genes prevent the correction of DNA errors. Consequently, mutations begin to accumulate exponentially within the cell genome, ultimately resulting in malignant transformation.
Clinical practice identifies several severe hereditary disorders directly associated with defects in DNA repair systems. The presence of these syndromes significantly increases the risk of malignancies:
- Hereditary non-polyposis colorectal cancer (Lynch syndrome).
- Xeroderma pigmentosum.
- Bloom syndrome.
- Fanconi anemia.
- Ataxia-telangiectasia.
Molecular Basis of Multistep Carcinogenesis
Modern pathology relies on the theory of multistep carcinogenesis. According to this concept, a malignant tumor never arises spontaneously from a single genetic defect; rather, its development is the cumulative result of long-standing, strictly sequential genetic events. The foundation of this process is the complex interplay between oncogenes and tumor suppressor genes.
For a normal cell to transform into a cancer cell, it must accumulate a large number of significant genetic anomalies. Molecular research statistics show that colorectal and breast carcinoma cells accumulate an average of about 90 mutant genes, with roughly 11 classified as "frequently mutated genes" per tumor.
It is important to note that not all genetic alterations are functionally equivalent. Mutations in tumor tissue are broadly divided into two principal categories:
- Driver mutations — alterations that directly drive malignant transformation and subsequent tumor progression.
- Passenger mutations — entirely neutral mutations that accumulate passively simply due to the extreme instability of the tumor genome.
Oncogene Combination and Mutation Specialization
A key feature of carcinogenesis is that full malignant transformation is triggered only by combinations of different mutations. Each individual oncogene specializes in conferring specific properties to the malignant phenotype of a tumor cell.
- A prime example of this specialization is the RAS oncogene. Its activation leads to several critical changes:
- Stimulates cellular interaction with growth factors, sharply increasing cellular sensitivity to them.
- Confers anchorage independence — the unique ability of a tumor cell to grow and divide without attachment to a solid extracellular matrix.
- Induces cellular immortality.
However, this is insufficient to produce full-blown cancer. As demonstrated in experiments involving mouse fibroblasts, only the combined, synergistic action of multiple oncogenes—such as the combination of RAS and MYC—can induce complete malignant tissue transformation.
Evolutionary Defense Mechanisms and Their Evasion
The organism possesses powerful evolutionary mechanisms to suppress tumor growth. The primary ones include apoptosis (programmed cell death) and cellular senescence.
Normally, when regulatory systems function properly, the appearance of oncogenic signals does not result in cancer. For instance, hyperactivation of the RAS gene in a healthy cell is recognized as a threat, immediately triggering cellular senescence or apoptosis. The cell dies or permanently loses its capacity to divide, thereby protecting the organism.
To develop true cancer, a tumor cell must overcome these barriers. This is achieved through the mutational loss of multiple genes, including those directly regulating apoptosis and senescence. The loss of this control enables the acquisition of progressive malignant phenotypic traits and unrestrained tumor growth.